NCT06965309 - Efficacy and Safety of HN2301 in Refractory Myasthenia Gravis(MG) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

May 31, 2026

Study Completion Date

December 30, 2026

Conditions

Refractory Myasthenia Gravis

Interventions

DRUG

HN2301 injection

Description: Three dose groups were set up, starting from the low dose group and climbing to explore the safe and effective dose.

Trial Locations (1)

RECRUITING

Shanghai General Hospital (Songjiang Branch) of Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors

collaborator

Songjiang Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

UNKNOWN

lead

Shenzhen MagicRNA Biotechnology Co., Ltd

INDUSTRY